Pre-made Pacmilimab biosimilar ( Whole mAb, anti-PDL1 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-422
Anti-PDL1 therapeutic antibody (Pre-made Pacmilimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Pacmilimab (also known as CX 072) is a recombinant antibody prodrug composed of a monoclonal antibody, being developed by CytomX Therapeutics, for the treatment of solid tumours and breast cancer. Pacmilimab is developed using the company's ProbodyTM technology platform.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-PDL1 therapeutic antibody (Pre-made Pacmilimab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Solid tumours;Lymphoma|